BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 28
• 29
• 30
• 31

• Drug Development

  Sunovion Pharmaceuticals Inc. Announces Results Of Health Outcomes Analyses Exploring The Effectiveness Of Aptiom (Eslicarbazepine Acetate) In People With Partial-Onset Seizures

  December 7, 2015

   · 

  14 min read
• Drug Development

  ADC Therapeutics Announces Positive Pre-clinical Results For Two Of Its Novel Adcs At The American Society of Hematology Conference

  December 7, 2015

   · 

  2 min read
• Drug Development

  Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of First-In-Class Selective CDK7 Inhibitor In Models Of Acute Leukemias

  December 7, 2015

   · 

  3 min read
• Drug Development

  Bellicum Announces BPX-501 Clinical Data Demonstrating Disease-Free Outcomes In Patients With Genetic Diseases

  December 7, 2015

   · 

  7 min read
• Drug Development

  GlycoMimetics, Inc. Presents At American Society of Hematology Meeting First-In-Human Data Showing Favorable Safety, Metabolic And Biomarker Profiles For GMI-1271

  December 7, 2015

   · 

  4 min read
• Drug Development

  Celgene And Acceleron Pharma Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society of Hematology Annual Meeting And Exposition

  December 7, 2015

   · 

  7 min read
• Drug Development

  Johnson & Johnson Announces Completion Of Novira Therapeutics Acquisition

  December 7, 2015

   · 

  3 min read
• Drug Development

  Sunesis Announces Presentation Of Results From Washington University Sponsored Phase 1/2 Trial Of Vosaroxin In MDS And VALOR Analysis Of Baseline Safety Predictors At Washington University Annual Meeting

  December 7, 2015

   · 

  7 min read
• Drug Development

  Incyte Release: Phase 3 RESPONSE-2 Study of Jakafi (ruxolitinib) Meets Primary Endpoint

  December 7, 2015

   · 

  7 min read
• Drug Development

  Incyte Release: Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi (Ruxolitinib) In Patients With Myeloproliferative Neoplasms(MPNs)

  December 7, 2015

   · 

  12 min read